Volatile organic compounds emitted from faeces as a biomarker for colorectal cancer

scientific article published on 03 March 2019

Volatile organic compounds emitted from faeces as a biomarker for colorectal cancer is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1111/APT.15140
P932PMC publication ID6593415
P698PubMed publication ID30828825

P50authorGeorgina L. HoldQ61912899
Christopher Sj ProbertQ90014617
Ashley BondQ90073845
Stephen LewisQ92091595
Bernard M. CorfeQ47189352
P2093author name stringPaul Rooney
Sanchoy Sarkar
Paul O'Toole
Rosemary Greenwood
Michael Burkitt
P2860cites workEffects of Curative Colorectal Cancer Surgery on Exhaled Volatile Organic Compounds and Potential Implications in Clinical Follow-up.Q51572808
A bacterial driver–passenger model for colorectal cancer: beyond the usual suspectsQ57709818
Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk populationQ81191664
Exhaled volatile organic compounds identify patients with colorectal cancerQ85613483
Adenoma detection rate and risk of colorectal cancer and deathQ88151880
The safety and sensitivity of a telemetric capsule to monitor gastrointestinal hydrogen production in vivo in healthy subjects: a pilot trial comparison to concurrent breath analysisQ90686294
Fusobacterium nucleatum infection is prevalent in human colorectal carcinomaQ24603069
Review article: next generation diagnostic modalities in gastroenterology--gas phase volatile compound biomarker detectionQ26995194
Current noninvasive tests for colorectal cancer screening: An overview of colorectal cancer screening testsQ28079672
Accuracy of screening for fecal occult blood on a single stool sample obtained by digital rectal examination: a comparison with recommended sampling practiceQ28303049
Detection of colorectal cancer (CRC) by urinary volatile organic compound analysisQ28543425
Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012Q29615661
Colorectal cancer screening by non-invasive metabolic biomarker fecal tumor M2-PK.Q33865884
Metab: an R package for high-throughput analysis of metabolomics data generated by GC-MS.Q33940342
Dysbiosis signature of fecal microbiota in colorectal cancer patientsQ34754690
MetaboAnalyst 3.0--making metabolomics more meaningfulQ35610559
Use of the Analysis of the Volatile Faecal Metabolome in Screening for Colorectal CancerQ35667382
Urinary Volatile Organic Compounds for the Detection of Prostate CancerQ35849909
Outcomes of the Bowel Cancer Screening Programme (BCSP) in England after the first 1 million testsQ36221516
Diagnostic accuracy of faecal occult blood tests used in screening for colorectal cancer: a systematic reviewQ36966177
The National Health Service Bowel Cancer Screening Program: the early yearsQ38125254
Colorectal cancer prevention in Europe: burden of disease and status of screening programsQ38188312
Faecal immunochemical tests versus guaiac faecal occult blood tests: what clinicians and colorectal cancer screening programme organisers need to knowQ38515202
Ingestible Sensors.Q38672251
Interval Colorectal Cancer Incidence Among Subjects Undergoing Multiple Rounds of Fecal Immunochemical TestingQ38797269
Microbial production of propanol.Q38855177
Investigation of Volatile Organic Compounds Emitted from Faeces for the Diagnosis of GiardiasisQ40982367
An updated Asia Pacific Consensus Recommendations on colorectal cancer screeningQ44457129
The potential of volatile organic compounds for the detection of active disease in patients with ulcerative colitisQ47964151
Volatile organic compounds in breath as markers for irritable bowel syndrome: a metabolomic approach.Q50516321
European guidelines for quality assurance in colorectal cancer screening and diagnosis. First Edition--Faecal occult blood testing.Q51315329
Impact on colorectal cancer mortality of screening programmes based on the faecal immunochemical test.Q51412952
P433issue8
P921main subjectfecesQ496
biomarkerQ864574
volatile organic compoundQ910267
colorectal cancerQ188874
colorectal carcinomaQ25493920
P304page(s)1005-1012
P577publication date2019-03-03
P1433published inAlimentary Pharmacology & TherapeuticsQ4726656
P1476titleVolatile organic compounds emitted from faeces as a biomarker for colorectal cancer
P478volume49

Reverse relations

cites work (P2860)
Q100694605A risk-stratified approach to colorectal cancer prevention and diagnosis
Q89910574Biomarkers for detecting colorectal cancer non-invasively: DNA, RNA or proteins?
Q90250266Digging deeper into volatile organic compounds associated with cancer
Q90101614Intestinal gases: influence on gut disorders and the role of dietary manipulations
Q92138830Volatile organic compounds in breath can serve as a non-invasive diagnostic biomarker for the detection of advanced adenomas and colorectal cancer

Search more.